OncologyTube Professional - Patients Click Here
21,134 video views
BeaconMedIC: Videos
09:08
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos.
by:BeaconMedIC | 48 views
15:36
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy.
by:BeaconMedIC | 54 views
03:39
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/po​or risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.
by:BeaconMedIC | 39 views
01:34
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Leht​inen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high or intermediate risk localized prostate cancer.
by:BeaconMedIC | 39 views
02:46
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASCO 2018.
by:BeaconMedIC | 28 views
03:02
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research.
by:BeaconMedIC | 41 views
02:02
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.
by:BeaconMedIC | 32 views
01:08
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer.
by:BeaconMedIC | 19 views
02:17
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.
by:BeaconMedIC | 53 views
02:18
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reporte​d quality of life on atezolizumab/be​vacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting.
by:BeaconMedIC | 13 views
dsfsd